Evidence map›Paper›PMID 39456891›Full record

ArticleInternational journal of molecular sciences2024

In Vitro Evaluation of New 5-Nitroindazolin-3-one Derivatives as Promising Agents against

Josué Pozo-Martínez, Vicente J Arán, Matías Zúñiga-Bustos, Sebastián Parra-Magna, Esteban Rocha-Valderrama, Ana Liempi, Christian Castillo, Claudio Olea-Azar, Mauricio Moncada-Basualto

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Pharmaceuticals (Basel, Switzerland) · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Josué Pozo-MartínezDepartment of Molecular Pharmacology and Clinical, Faculty of Medicine, University of Chile, Santiago 8380453, Chile.
Vicente J AránInstituto de Química Médica (CSIC), Juan de la Cierva 3, 28006 Madrid, Spain.ORCID 0000-0002-3390-7157
Matías Zúñiga-BustosInstituto Universitario de Investigación y Desarrollo Tecnológico, Universidad Tecnológica Metropolitana, Santiago 8940577, Chile.ORCID 0000-0003-2448-9376
Sebastián Parra-MagnaInstituto Universitario de Investigación y Desarrollo Tecnológico, Universidad Tecnológica Metropolitana, Santiago 8940577, Chile.
Esteban Rocha-ValderramaInstituto Universitario de Investigación y Desarrollo Tecnológico, Universidad Tecnológica Metropolitana, Santiago 8940577, Chile.
Ana LiempiPrograma de Biología Integrativa, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile.ORCID 0000-0003-3200-9811
Christian CastilloPrograma de Biología Integrativa, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile.ORCID 0000-0001-8710-6745
Claudio Olea-AzarDepartment of Molecular Pharmacology and Clinical, Faculty of Medicine, University of Chile, Santiago 8380453, Chile.
Mauricio Moncada-BasualtoInstituto Universitario de Investigación y Desarrollo Tecnológico, Universidad Tecnológica Metropolitana, Santiago 8940577, Chile.ORCID 0000-0003-1733-9126

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chagas disease is a prevalent health problem in Latin America which has received insufficient attention worldwide. Current treatments for this disease, benznidazole and nifurtimox, have limited efficacy and may cause side effects. A recent study proposed investigating a wide range of nitroindazole and indazolone derivatives as feasible treatments. Therefore, it is proposed that adding a nitro group at the 5-position of the indazole and indazolone structure could enhance trypanocidal activity by inducing oxidative stress through activation of the nitro group by NTRs (nitroreductases). The study results indicate that the nitro group advances free radical production, as confirmed by several analyses. Compound

Indexed as

IndazolesMolecular Docking SimulationTrypanocidal AgentsTrypanosoma cruziAnimalsChagas DiseaseReactive Oxygen SpeciesIndazolesReactive Oxygen SpeciesTrypanocidal Agents5-Nitroindazolin-3-onesapoptosis inductionchagas diseaseoxidative stresstrypanocidal activity

Identifiers

PMID39456891
PMCPMC11508334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.